Five-year analysis on the long-term effects of dabrafenib plus trametinib (D + T) in patients with BRAF V600–mutant unresectable or metastatic melanoma.
Year: 2019
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Paul D. Nathan, Caroline Robert, Jean Jacques Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Eugeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Michael A. Davies, Antoni Ribas, Keith Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Dirk Schadendorf, Georgina V. Long
Institutions: Mount Vernon Cancer Centre, Institut Gustave Roussy, Aix-Marseille Université, Moscow City Oncology Hospital №62, University Hospital Schleswig-Holstein, Institute of Oncology NN Petrov, Istituto Oncologico Veneto, Tel Aviv University, Sheba Medical Center, University of Tübingen, Dnipro State Medical University, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Harvard University, Massachusetts General Hospital, Dana-Farber Cancer Institute, Novartis (Switzerland), Essen University Hospital, The University of Sydney, Melanoma Institute Australia
Language: English
Topic: Melanoma and MAPK Pathways
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W2947834276